Medtronic MDT
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Medtronic (MDT) Business Model and Operations Summary
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Key Insights
Medtronic (MDT) Core Market Data and Business Metrics
Latest Closing Price
$88.49Market Cap
$113.81 BillionPrice-Earnings Ratio
26.90Total Outstanding Shares
1.28 Billion SharesTotal Employees
95,000Dividend
$0.70 Per Share QuarterlyIPO Date
July 28, 1980SIC Description
Electromedical & Electrotherapeutic ApparatusPrimary Exchange
New York Stock ExchangeHeadquarters
Building Two Parkmore Business Park West, Galway, L2, H91 4K49
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 25, 2024 to January 24, 2025
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $7.29 Billion |
| Net Cash Flow From Financing Activities | $-5.38 Billion |
| Exchange Gains/Losses | $-155 Million |
| Net Cash Flow From Investing Activities, Continuing | $-2.14 Billion |
| Net Cash Flow, Continuing | $-227 Million |
| Net Cash Flow From Financing Activities, Continuing | $-5.38 Billion |
Income Statement
January 25, 2024 to January 24, 2025
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations Before Tax | $5.22 Billion |
| Cost Of Revenue | $11.53 Billion |
| Net Income/Loss | $4.29 Billion |
| Provision For Loan, Lease, And Other Losses | $0 |
| Interest Expense, Operating | $748 Million |
| Operating Income/Loss | $5.57 Billion |
Comprehensive Income
January 25, 2024 to January 24, 2025
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $617 Million |
| Comprehensive Income/Loss | $4.91 Billion |
| Comprehensive Income/Loss Attributable To Parent | $4.88 Billion |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $26 Million |
Balance Sheet
January 25, 2024 to January 24, 2025
| Metric | Value |
|---|---|
| Other Non-current Assets | $48.68 Billion |
| Assets | $89.97 Billion |
| Accounts Payable | $2.29 Billion |
| Noncurrent Liabilities | $28.52 Billion |
| Current Assets | $22.51 Billion |
| Fixed Assets | $6.59 Billion |
Historical Dividends
Current dividend: $0.70 Per Share Quarterly
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| Mar 6, 2025 | Apr 11, 2025 | Mar 28, 2025 | $0.7 | Quarterly |
| Dec 5, 2024 | Jan 10, 2025 | Dec 27, 2024 | $0.7 | Quarterly |
| Aug 15, 2024 | Oct 11, 2024 | Sep 27, 2024 | $0.7 | Quarterly |
| May 22, 2024 | Jul 12, 2024 | Jun 28, 2024 | $0.7 | Quarterly |
| Mar 7, 2024 | Apr 12, 2024 | Mar 22, 2024 | $0.69 | Quarterly |
| Dec 7, 2023 | Jan 12, 2024 | Dec 20, 2023 | $0.69 | Quarterly |